Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.
Toledo R, Calahorro García A, Mirallas O, Moreno A, Galvao V, Alonso G, Vieito M, Brana I, Oberoi A, Lostes-Bardaji M, Jimenez J, Sanz M, Viaplana C, Perez-Lopez R, Nuciforo P, Abbott C, Pugh J, Chen R, Boyle S, Garralda E. Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials. Journal Of Clinical Oncology 2024, 42: 2510-2510. DOI: 10.1200/jco.2024.42.16_suppl.2510.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsPhase 1 clinical trialMolecular residual diseaseCheckpoint inhibitorsCtDNA levelsICI responseDetection of molecular residual diseaseDynamics of circulating tumor DNATreated with immune checkpoint inhibitorsDuration of PFSRefractory metastatic tumorsImmune checkpoint inhibitionAccurate patient managementLiquid biopsy testingTreatment cycle 3Levels of ctDNAStage IV cancer patientsLiquid biopsy platformPan-cancer cohortAssociated with significant increasesSequencing of tumorsWhole-genome sequencing of tumoursCtDNA clearanceCtDNA dynamicsCtDNA monitoring